Next Phase Newsletter

A $50 million strategic corporate venture capital fund formed by an oncology-focused pharmaceutical company seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the U.S., Europe and Japan. and opportunities mainly in US and Europe.

The firm considers a wide variety of modalities (both biologics and small molecules) within the oncology field. The firm focuses on programs from drug discovery to preclinical development.

The firm is looking for teams with strong sector expertise. With the support of the parent company’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate venture capital fund based in Europe with offices worldwide invests in medical technology companies that are strategically relevant to its parent company. Investments in equity rounds range from $1-5 million, and are made worldwide.

The fund’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the fun focuses on products used in a hospital setting. The firm also invests in healthcare IT solutions that add value to imaging and diagnostics, such as data-as-a-service products. The fund is potentially interested in medical robotics. The fund will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharma firm has created an independent R&D innovation unit to transform early stage innovations into solutions for improving the lives of people with skin disease; the unit is an agile group of scientific experts with an entrepreneurial mindset and a vision to enable precision medicine in Dermatology. The group looks to accelerate breakthrough research projects and technologies by offering scientific expertise and funding to people with great ideas. The group employs a flexible co-funding model and deal structures may vary widely from grants, convertible bonds, equity positions etc. Investments range up to 5 million USD. The unit hub also leverages their large, world-class dermatology network to accelerate projects e.g. help validate novel targets in relevant skin diseases or develop advanced diagnostic technologies.

The firm is exclusively focused on skin diseases, with the vision to enable precision medicine in dermatology. The group’s research focus areas include deep learning, imaging technologies and non-invasive bio-marker technologies. Additionally, the unit continuously explores novel therapeutics (small molecules, biologics, gene therapy, etc.), medical devices, diagnostic technologies etc. that have application in dermatologic indications. The group is open to new ideas and is excited to discuss any opportunities that improve the quality of life of people living with skin disease.

The firm has no strict requirements for companies or management teams and will work with a variety of institutions and entrepreneurs. The group collaborates for the very purpose of advancing science and all collaborations are based on mutual trust and transparency.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Europe that focuses solely on the life sciences is investing from their third fund and is actively looking for new investments, usually in Series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America with more of a focus on the U.S.

The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is somewhat less interested in diagnostic technologies. The firm is generally agnostic in terms of subsectors and indications with the primary focus on products that address clear unmet opportunities. Historically, the firm has invested in biotech therapeutics that address a wide variety of inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A medical technology venture firm based in New England makes equity investments in early stage companies developing products for to accelerate the trend of precision medicine diagnostics. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharma firm headquartered in Tokyo, Japan focuses on two main sectors: pharmaceutical and medical device for home healthcare. The company is seeking innovative medical technologies to strengthen its pipeline while expanding into new areas. The company is looking for in-licensing and collaborative R&D opportunities in the US, Canada, EU, and Israel.

The firm has existing businesses in respiratory diseases, cardiovascular disease, and orthopedics. The firm is seeking innovative, home-care, therapeutic medical devices in the disease sectors described above. The firm is also interested in home patient monitoring products. In addition, the firm is looking for innovations in the following areas: neurological disorders such as stroke, depression, Parkinson’s disease, etc.; cancer; wound care; and rehabilitation, which are all must be used at home care. The company is most interested in PMA and de novo therapeutic devices in the home-care settings. The company prefers assets with initial patient data. Furthermore, the firm is seeking opportunities in digital medicine business (but not for consumer products) in disease areas described above.

Within pharmaceuticals, the firm is looking for late clinical stage assets in orthopedics, respiratory diseases, and cardiovascular diseases. The firm is most interested in small molecule and peptide drugs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Philadelphia, PA provides expansion and growth capital to commercial-stage companies in select healthcare sectors. The firm recently closed its first fund in June of 2016 at $200M, and is targeting initial equity investments around $10M with up to another $5M-$10M in additional capital reserved for follow-on investments. The partners of the firm have significant experience investing in and building healthcare companies, and look to leverage their operational experience to help portfolio companies grow and scale. The firm is focused on US-based companies, and prefers to lead rounds but will also participate as a minority investor in a syndicate. The firm is targeting 3-4 investments per year.

The firm is focused on commercial-stage companies within specialty pharmaceutical, medical technology, healthcare services and digital health that are generating at least $5M in revenue. It is not a requirement that the company have positive EBITDA, but should be anticipating positive cash flow within 18 months. 1315 Capital has particular interest in obesity prevention, opioid addiction, podiatry and cosmeceuticals.

The firm prefers to work with experienced management teams and typically avoids first time entrepreneurs, but will evaluate companies with a great product and complete management team. The firm prefers to work with companies that have more than one product. The firm does seek a board seat along with investment and prefers to be involved with the management team, given the firm’s expertise in operations and ability to directly help the company scale.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com